WO2008038807A1 - Composition dermatologique à usage externe - Google Patents
Composition dermatologique à usage externe Download PDFInfo
- Publication number
- WO2008038807A1 WO2008038807A1 PCT/JP2007/069111 JP2007069111W WO2008038807A1 WO 2008038807 A1 WO2008038807 A1 WO 2008038807A1 JP 2007069111 W JP2007069111 W JP 2007069111W WO 2008038807 A1 WO2008038807 A1 WO 2008038807A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- bht
- external
- composition
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000002245 particle Substances 0.000 claims description 32
- 229920003169 water-soluble polymer Polymers 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 38
- 239000007787 solid Substances 0.000 abstract description 9
- 230000000638 stimulation Effects 0.000 abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 4
- 208000006877 Insect Bites and Stings Diseases 0.000 abstract description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 49
- 230000007803 itching Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 230000007794 irritation Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 10
- -1 polyethylene Polymers 0.000 description 10
- 239000003814 drug Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000005722 itchiness Effects 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- ZRTQSJFIDWNVJW-WYMLVPIESA-N Lanoconazole Chemical compound ClC1=CC=CC=C1C(CS\1)SC/1=C(\C#N)N1C=NC=C1 ZRTQSJFIDWNVJW-WYMLVPIESA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- ARZLUCYKIWYSHR-UHFFFAOYSA-N hydroxymethoxymethanol Chemical compound OCOCO ARZLUCYKIWYSHR-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229950010163 lanoconazole Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Definitions
- the present invention relates to a composition for external use on skin having an itching suppression effect, a massage effect and the like.
- the power of performing massage or the like to obtain a beauty or relaxation effect For example, the power of performing massage or the like to obtain a beauty or relaxation effect.
- water-insoluble particles are blended as a scrub agent in order to exert a massage effect by physical stimulation.
- scrubbing agents hard scrubbing agents such as polyethylene beads, talmi shell grains, and crystalline cellulose are widely used. Although hard scrubs are excellent in removing dirt on the skin and in massaging the skin, there are cases in which unpleasant skin irritation or foreign body sensation is felt during use.
- itch is defined as “a sensation that causes the skin to break! /, And! /”, And is generally an unpleasant sensation.
- Symptoms associated with “itch” include various forms such as atopic dermatitis, urticaria, insect bites, dry skin, and hypersensitive skin.
- antihistamines, local anesthetics, moisturizing Agents are used. However, since they penetrate into the inner surface of the skin and involve a scientific approach, it takes time to take effect.
- Patent Document 1 discloses an external preparation for skin containing natural oils and fats and antioxidants.
- butylhydroxytoluene is generally added in an amount of about 0.0 ;! to 1% as a preservative, stabilizer, antioxidant and the like.
- these external preparations have also been unable to effectively suppress the skin rather than those intended to irritate the skin.
- Patent Document 1 JP 2000-159678 Disclosure of the invention
- the main object of the present invention is to provide an external preparation for skin that gives skin irritation by application and exhibits a comfortable massage effect.
- Another object of the present invention is to provide an external composition for skin, which can replace itching caused by insects and hypersensitivity skin with irritation, and can effectively suppress itching. Is.
- BHT ptylhydroxytonolene
- the present invention provides the following external composition for skin.
- Item 1 A composition for external use on skin, characterized by containing solid-state butylhydroxytoluene (hereinafter referred to as BHT).
- BHT solid-state butylhydroxytoluene
- Item 2 The external composition for skin according to Item 1, wherein the particle size of BHT is 1000 m or less.
- Item 4 The composition for external application to skin according to any one of Items 1 to 3, wherein the BHT content is 10 to 40% by weight.
- Item 5 The external composition for skin according to any one of Items 1 to 4, further comprising a water-soluble polymer.
- the invention's effect [0009]
- the external composition for skin according to the present invention is applied directly to the skin, and the BHT in a solid state physically stimulates the skin, so that an appropriate massage stimulus can be given to the skin.
- the composition for external use of the skin of the present invention when applied to an affected area having itching, it can be replaced with a feeling of irritation in a short time by physical stimulation of BHT in a solid state, and the itching is effectively suppressed. can do.
- composition for external use of the skin of the present invention is characterized mainly by containing BHT in a solid state.
- BHT BHT
- the antipruritic agent of this invention contains BHT as an essential component.
- Ptylhydroxytoluene is a compound having a white crystal shape, and both 1S, also called dibutylhydroxytoluene, refer to the same compound ([(CH 3) C] C H (CH 2) OH).
- BHT traditionally makeup
- antioxidants and stabilizers for foods, pharmaceuticals, foods and the like.
- BHT commercially available ones can be used.
- butyl hydroxytoluene (Sanei Chemical Co., Ltd.), dibutylhydroxytoluene (Eastman Chemica Norre Japan Co., Ltd., Ueno Pharmaceutical Co., Ltd.) API Corporation, Sumitomo Chemical Co., Ltd., Nagase Sangyo Co., Ltd., JGC Universal Co., Ltd., Mitsubishi Wel Pharma Co., Ltd.).
- the particle size of BHT used in the present invention is about lOOOO ⁇ m or less, preferably about 1000 to 50 to 111, more preferably about 1000 to; about 100 to m, more preferably about 1000 to; About 180 in.
- BHT having each particle diameter can be obtained by pulverizing BHT with a mortar or the like and then applying it to a sieve having each diameter.
- Preferred combinations include, for example, (a) 501-; about 1000 m A combination of BHT with a particle size of and ⁇ having a particle size of about 350 to 500 ⁇ m; (b) BHT with a particle size of less than 350 [Im and a particle size of about 350 to 500 ⁇ m A combination of BHT having
- the blending ratio of BHT having each particle size is appropriately set as long as the substitution effect on the irritating feeling of itchiness can be exhibited.
- BHT having a particle size of about 501 to 1000 m is set to 0.
- the amount of BHT in the external composition for skin of the present invention is about 10 to 40% by weight, preferably about 15 to 35% by weight, more preferably about 20 to 30% by weight. With such a blending amount, the massage effect and the antipruritic effect due to skin irritation can be exhibited more significantly while maintaining the stability as a preparation.
- the composition for external use of the present invention preferably contains alcohol in addition to the BHT.
- alcohol By blending alcohol, solid-state BHT can be dispersed favorably, and the skin can be uniformly and moderately stimulated.
- the alcohol used in the present invention is not particularly limited as long as it is commonly used in the fields of cosmetics and pharmaceuticals. For example, methanol, ethanol, propanol, isopropanol, butanol, isobutanol and the like are used.
- Lower alcohol having 1 to 6 carbon atoms, preferably 1 to 3 carbon atoms; propylene glycol, dipropylene glycol, glycerin, 1,3-butylene glycol, butylene glycol, concentrated glycerin, polyethylene glycol, maltitol, mannitol, sorbitol, etc.
- Examples include polyhydric alcohols. these May be used alone or in combination of two or more.
- the lower alcohol may be anhydrous or hydrated. In the present invention, it is preferable to use (hydrous) ethanol, absolute ethanol, or isopropanol!
- the blending amount of alcohol in the composition for external use of the present invention is about 0 to 45% by weight, preferably about 4 to 40% by weight, more preferably about 4 to 35% by weight.
- the blending ratio of BHT and alcohol in the external composition for skin of the present invention is such that when BHT is 1 part by weight, alcohol is about 3 parts by weight or less, preferably about 2 parts by weight or less, and more preferably about 1 part by weight or less. With such a blending ratio, the solid state of BHT can be maintained and an appropriate stimulus can be given to the skin.
- the external composition for skin of the present invention may contain water, a water-soluble polymer, or the like, if necessary.
- Conventionally known water-soluble polymers can be used, for example, carboxyvininole polymer, polyvinyl alcohol, polyvinyl methyl ether, polyvinylinoxychetyl cellulose, pullulan, agar, gelatin, alginic acid and its salts, carrageen Examples include naan and gums. These may be used alone or in combination of two or more.
- the amount of water in the external composition for skin of the present invention is about 25 to 89.5% by weight, preferably about 27 to 80.2% by weight, more preferably about 28 to 75% by weight;
- the amount of the conductive polymer to be combined is about 0.5 to 5% by weight, preferably about 0.8 to 4% by weight, and more preferably about 1 to 3% by weight.
- Typical formulation examples of the present invention 10 to 40 weight BHT 0/0, the Anorekonore 0-45 wt%, a water-soluble polymer 0.5 to 5% by weight, water 25-89.
- a composition for external use containing 5% by weight is exemplified.
- the composition for external use of the skin of the present invention includes various components generally used in cosmetics, quasi-drugs, pharmaceuticals, aqueous components, oil-based components, moisturizing components, moisturizing components, and so on.
- Forms, thickeners, preservatives, antioxidants, pH adjusters, carriers, fragrances, colorants, drugs and the like can be prepared in various dosage forms alone or in combination of two or more.
- the composition for external use of the skin of the present invention includes a known local anesthetic and antibacterial agent within the range not impairing the effects of the present invention.
- local anesthetics such as lidocaine, dibu force in, dibu force in hydrochloride, diphenhydramine, ethyl aminobenzoate, desitthecin; chlorpheniramine maleate, diphenhydramine, diphenhydramine hydrochloride, glycyrrhetinic acid, glycyrrhizin
- Anti-inflammatory agents such as dipotassium phosphate, monoammonium glycyrrhizinate, allantoin, methyl salicylate; 1-menthol nole, dl-menthol nole, camphor, dl-strengthen, lactic acid menthylate, etc .
- Moisturizers such as urea, salicylic acid, sodium hyaluronate
- Bactericides such as isopropylmethyl phenol, quaternary ammonium salts (benzalkonium chloride, benzethonium chloride, etc.), chlorhexidine hydrochlor
- Examples of the dosage form of the external composition for skin of the present invention include force S that can be prepared into a conventionally known dosage form according to the method of use and application, such as an ointment, lotion, gel, aerosol, and the like. It is done.
- the external composition for skin of the present invention contains an appropriate amount of a base for obtaining a desired dosage form.
- a base for example, but not limited to, paraffin, petrolatum, squalane, norafin, white wax, plastibase, polyethylene glycolenore, macrogonole, lauromacronore, silicone oil, silicone, polysorbate, polyoxyethylene hydrogenated castor oil, Oil bases such as olive oil, cottonseed oil, soybean oil, coconut oil; higher alcohols such as cetanol and stearyl alcohol; fatty acid esters (such as isopropyl myristate and sorbitan fatty acid ester), higher fatty acid salt emulsifiers, highly refined egg yolk lecithin , Soybean lecithin, refined soybean lecithin, white beeswax, propylene carbonate, egg yolk phospholipid, egg yolk oil, coconut oil fatty acid, sodium lauryl sulfate, other ionic and nonionic surfactants
- the composition for external use of the present invention can be prepared by mixing and preparing the above components according to a conventionally known method. Conditions such as temperature in preparation, order of addition of each component, mixing time, etc. should be set as appropriate based on the common general technical knowledge according to the physical or scientific properties of each component, concentration, instrument stress, etc. Is not particularly limited.
- the external preparation for skin of the present invention comprises For example, it can be prepared by dissolving components soluble in water and alcohol, mixing them and stirring them uniformly, and finally adding BHT.
- composition for external use of the skin of the present invention can be applied as an antipruritic agent, athlete's foot drug or the like to a place where itching occurs.
- the application target is not particularly limited as long as it is used for this purpose, but for example, when used as an antipruritic agent, it can be applied to symptom accompanied by itching, insect bite, dry skin, hypersensitive skin, etc. .
- itch refers to "a feeling that causes the idea of wanting to break through the skin” as described above.
- an appropriate amount of the external composition for skin of the present invention may be spread over the itchy part of the skin.
- the solid BHT can physically irritate the itchy part of the skin, replace the itching with a feeling of irritation, and suppress the itching without further rebating.
- “replacing itching with a sense of irritation” refers to making the skin sensation in a short-term (instantaneous) state of feeling an irritation (feeling itchy) other than “itching”.
- the skin irritation by the external preparation for skin of the present invention is an appropriate stimulation without damaging the skin, and thus can be used for promoting blood circulation at the application site. Therefore, the external preparation for skin of the present invention can also be used as a massage agent, an external anti-inflammatory analgesic or the like.
- the obtained external composition for skin was stored at room temperature (about 25 ° C) for 1 week, and its properties were visually confirmed to evaluate the stability. Specifically, dispersibility (presence / absence of particle settling and agglomeration (aggregation of particles)), shape retention (presence / absence of obvious changes compared to initial properties such as viscosity reduction), and particles are solid It was confirmed whether the properties were maintained (softening / dissolution). When there was no change in any of these properties, it was marked as ⁇ , and when any one of the changes was confirmed, it was marked as X.
- composition for external use with a stability evaluation result of “ ⁇ ” was applied to the affected area of 10 subjects complaining of itching caused by insect bites, etc., and it was easy to apply (one point when it was difficult to apply) 5 points when easy to apply), replacement of itching with irritation (1 point when not replaced with irritation, 5 points when replaced with irritation) and anti-itching effect (when itching does not stop) 1 point and 5 points when itching stops) were evaluated in 5 stages each.
- composition for external application on skin was applied to the skin of 10 healthy subjects, and with regard to comfortable physical irritation (1 point when not felt, 5 points when felt) Evaluation was performed.
- Table 1 shows the evaluation results.
- CVP represents carboxybulle polymer and PG represents propylene glycol.
- composition for external use with skin containing particles other than BHT (Comparative Examples;! -32) was also evaluated in the same manner. The results are shown in Table 2-1 and Table 2-2 below.
- CVP represents a carboxybule polymer
- PG represents propylene glycol
- Comparative Examples 9 to 13, 16, 25 to 29, and 32 are compositions for external use in skin that contain conventionally known particles. These external preparations for skin were relatively stable and good, but all of them had a replacement effect on the irritating feeling of itchiness and a pleasant stimulating action. In the preparations in which BHT was dissolved, it was not possible to obtain a sensation of itchiness or a pleasant irritation (data not shown).
- the composition for external use of the skin of the present invention has an excellent anti-itching effect as well as a temporary anti-itching effect of replacing itching with a stimulating feeling. That is, the external composition for skin of the present invention has an immediate and long-lasting itch suppression effect.
- CVP carboxybutyl polymer
- PG propylene glycol
- HPC hydroxypropyl cellulose
- DPG dipropylene glycol
- 1,3-BG 1,3-butylene glycol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une composition dermatologique à usage externe capable de produire une sensation physique de stimulation sur la peau, et de remplacer le prurit causé en particulier par des piqûres d'insectes ou une hypersensibilité de la peau par une sensation de stimulation, de façon à supprimer efficacement le prurit. Cette composition dermatologique à usage externe est caractérisée en ce qu'elle contient du butylhydroxytoluène sous forme solide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006270076A JP5063072B2 (ja) | 2006-09-29 | 2006-09-29 | 皮膚外用組成物 |
JP2006-270076 | 2006-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008038807A1 true WO2008038807A1 (fr) | 2008-04-03 |
Family
ID=39230237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/069111 WO2008038807A1 (fr) | 2006-09-29 | 2007-09-28 | Composition dermatologique à usage externe |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5063072B2 (fr) |
WO (1) | WO2008038807A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2493955A (en) * | 2011-08-25 | 2013-02-27 | Hds Ltd | Methods and compositions for reducing allergic reactions to fragranced products and perfumes |
WO2021204568A1 (fr) | 2020-04-07 | 2021-10-14 | Universität Basel | Composition topique pour le traitement du prurit |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07126158A (ja) * | 1993-10-27 | 1995-05-16 | Taisho Pharmaceut Co Ltd | クロタミトン配合外用剤 |
JPH07173078A (ja) * | 1993-12-21 | 1995-07-11 | Taisho Pharmaceut Co Ltd | 鎮痒剤組成物 |
JPH1036883A (ja) * | 1996-07-16 | 1998-02-10 | Asahi Chem Ind Co Ltd | 皮膚および頭髪洗浄剤組成物 |
JPH10330217A (ja) * | 1997-05-29 | 1998-12-15 | Kose Corp | 美白用皮膚外用剤 |
JPH11106307A (ja) * | 1997-09-30 | 1999-04-20 | Pola Chem Ind Inc | 亜硫酸塩含有石鹸 |
JP2004256805A (ja) * | 2003-02-07 | 2004-09-16 | Kao Corp | 枠練り石鹸組成物 |
WO2004078157A2 (fr) * | 2003-03-04 | 2004-09-16 | The Procter & Gamble Company | Regulation de la croissance des poils chez les mammiferes |
WO2005018320A1 (fr) * | 2003-08-12 | 2005-03-03 | The William M. Yarbrough Foundation | Composition pour le traitement lie aux organismes piquants et penetrants et aux parasites, et pour le traitement de l'urticaire, et procede d'utilisation |
-
2006
- 2006-09-29 JP JP2006270076A patent/JP5063072B2/ja active Active
-
2007
- 2007-09-28 WO PCT/JP2007/069111 patent/WO2008038807A1/fr active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07126158A (ja) * | 1993-10-27 | 1995-05-16 | Taisho Pharmaceut Co Ltd | クロタミトン配合外用剤 |
JPH07173078A (ja) * | 1993-12-21 | 1995-07-11 | Taisho Pharmaceut Co Ltd | 鎮痒剤組成物 |
JPH1036883A (ja) * | 1996-07-16 | 1998-02-10 | Asahi Chem Ind Co Ltd | 皮膚および頭髪洗浄剤組成物 |
JPH10330217A (ja) * | 1997-05-29 | 1998-12-15 | Kose Corp | 美白用皮膚外用剤 |
JPH11106307A (ja) * | 1997-09-30 | 1999-04-20 | Pola Chem Ind Inc | 亜硫酸塩含有石鹸 |
JP2004256805A (ja) * | 2003-02-07 | 2004-09-16 | Kao Corp | 枠練り石鹸組成物 |
WO2004078157A2 (fr) * | 2003-03-04 | 2004-09-16 | The Procter & Gamble Company | Regulation de la croissance des poils chez les mammiferes |
WO2005018320A1 (fr) * | 2003-08-12 | 2005-03-03 | The William M. Yarbrough Foundation | Composition pour le traitement lie aux organismes piquants et penetrants et aux parasites, et pour le traitement de l'urticaire, et procede d'utilisation |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2493955A (en) * | 2011-08-25 | 2013-02-27 | Hds Ltd | Methods and compositions for reducing allergic reactions to fragranced products and perfumes |
WO2021204568A1 (fr) | 2020-04-07 | 2021-10-14 | Universität Basel | Composition topique pour le traitement du prurit |
Also Published As
Publication number | Publication date |
---|---|
JP5063072B2 (ja) | 2012-10-31 |
JP2008088100A (ja) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110403833B (zh) | 用于增强碱性有益剂的局部施用的组合物及方法 | |
CA2567575C (fr) | Formulations a base d'organogel destinee a des applications therapeutiques | |
JP5694665B2 (ja) | 局所製剤とその用法 | |
JP4133837B2 (ja) | 皮膚保湿用ゲルおよび方法 | |
US20060078579A1 (en) | Organo-gel formulations for therapeutic applications | |
JP2009184951A (ja) | 皮膚外用剤組成物 | |
JPH0215023A (ja) | 麻酔性/皮膚加湿組成物およびその製造方法 | |
JP2015530380A (ja) | 乾癬を治療するための組成物 | |
JP2000143486A (ja) | 皮膚外用剤 | |
JP2002212107A (ja) | 局所適用組成物 | |
CN1357321A (zh) | 减少炎症和红斑的方法 | |
JP2012092067A (ja) | 非ステロイド性消炎鎮痛外用剤 | |
WO2008038807A1 (fr) | Composition dermatologique à usage externe | |
EP1014926B1 (fr) | Compositions cosmetiques et therapeutiques, leurs utilisation et procede de preparation | |
JP5565995B2 (ja) | 鎮痒剤 | |
WO2002036130A1 (fr) | Composition veterinaire pour le traitement topique de la peau traumatisee ou enflammee | |
JP7312527B2 (ja) | 乳化組成物 | |
CN114746077A (zh) | 个人护理组合物及用于其的方法 | |
KR102781432B1 (ko) | Msm(식이유황)을 이용한 관절통증 및 근육통증 회복을 위한 조성물 및 그 제조방법 | |
JP7329910B2 (ja) | 皮膚外用組成物 | |
JP7678657B2 (ja) | 皮脂分泌促進剤 | |
JPH08165244A (ja) | 皮膚疾患治療剤 | |
US20240180837A1 (en) | Method for Treating Inflammatory Skin Conditions and other Topical Conditions or Disorders | |
JP2022178149A (ja) | 外用組成物 | |
JP2000143518A (ja) | 皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07828852 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07828852 Country of ref document: EP Kind code of ref document: A1 |